Intrathecal Baclofen Pump versus Escalating Oral Therapy for Severe Spasticity
A single patient with post-spinal-cord-injury spasticity already near his maximal tolerated oral dose. The disagreement is whether a more effective delivery route is worth a rare but life-threatening withdrawal risk for a patient with real gaps in his own follow-up.
M.A., a 34-year-old former warehouse supervisor, has used a wheelchair since a traumatic spinal cord injury five years ago left him with a T10-level lesion, and the spasticity that followed has only worsened since — tight enough now, despite oral baclofen pushed to 20 milligrams four times daily — 80 milligrams a day, the labeled maximum for oral baclofen — that transfers and positioning have become genuinely difficult again. His Modified Ashworth Scale scores 3 to 4 bilaterally even on that dose, and the dose itself has started costing him something separate from the spasticity: daytime somnolence that now limits his wheelchair mobility and the part-time work he'd only recently returned to. He lives with his partner, who helps with daily care, but two hours from the nearest specialty clinic, and has missed two of his last six scheduled follow-up visits.
Penn and colleagues established the case for this route in 1989, in a randomized double-blind crossover trial confined to patients whose spasticity had already failed oral baclofen — precisely where M.A. now sits. Intrathecal baclofen delivers the drug directly into the cerebrospinal fluid at roughly a hundredth of the oral dose equivalent, achieving comparable or better spasticity control while largely sparing the systemic sedation that's now limiting further oral escalation for M.A. specifically. That advantage comes with a real surgical procedure and a risk unique to this delivery route: abrupt intrathecal baclofen withdrawal, from a failed catheter, a malfunctioning pump, or a missed refill, is a described, life-threatening syndrome — high fever, rebound severe spasticity, and rhabdomyolysis — that oral baclofen, whatever its own downsides, simply cannot produce. M.A.'s two missed follow-up visits aren't incidental to that risk; they're exactly the kind of gap the withdrawal syndrome depends on to go unrecognized until it's severe.
A more effective route, and a withdrawal risk that depends on follow-up
I'd proceed to pump placement. He's at 80 milligrams a day, the labeled ceiling for oral baclofen and it's still not controlling his spasticity adequately, while the sedation it's causing is now costing him mobility and work independently of the tone problem itself. Intrathecal delivery achieves comparable or better control at roughly a hundredth of the oral dose, which should let us largely get the sedation back without giving up on tone control.
I don't dispute the efficacy or sedation-avoidance advantage of intrathecal delivery in general. What I want named explicitly is the risk unique to this route: abrupt intrathecal baclofen withdrawal, from a failed catheter or a missed refill, is a described, life-threatening syndrome — high fever, rebound severe spasticity, rhabdomyolysis — that his current oral regimen, whatever its own limitations, simply cannot cause.
That risk isn't abstract for M.A. specifically — he's missed two of his last six scheduled follow-up visits, living two hours from clinic. A therapy whose worst-case failure mode depends on reliable, timely follow-up to catch is a materially different proposition for a patient who has already demonstrated real gaps in that follow-up.
I think the withdrawal risk is real and needs to be taken seriously, but it's a function of infrastructure and education, not an inherent reason to withhold a more effective delivery route from someone who needs it. I'd proceed to pump placement, but only alongside a structured plan built specifically around his access gap: explicit written and verbal withdrawal-symptom education for M.A. and his partner, a scheduled refill-reminder system with redundant contact methods, and a clear, direct instruction on when to seek emergency care rather than wait for the next specialty appointment.
That directly addresses the specific mechanism of the risk the Clinical Pharmacologist named — missed follow-up — rather than treating his access limitations as a reason to accept ongoing undertreated spasticity and sedation instead.
Agreed: pump placement proceeds, paired with explicit withdrawal-symptom education for M.A. and his partner and a redundant refill-reminder system addressing his specific follow-up gap.
Not agreed: whether his missed-visit history should have weighed more heavily against proceeding at all. The Clinical Pharmacologist's underlying concern about follow-up reliability wasn't resolved, only addressed with additional infrastructure built around it.